Compare Dicks Sporting Goods Inc (DKS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Novo Nordisk A/S — how do they compare? Dicks Sporting Goods Inc trades at $203.31 (market cap $18.35B), while Novo Nordisk A/S trades at $46.24 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 11.3× Dicks Sporting Goods Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| DKS | NVO | |
|---|---|---|
Market Cap | $18.35B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $63.98 |
52-Week Low | $187.78 | $35.29 |
Enterprise Value | $25.14B | $222.55B |
Dividend Yield | 2.44% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dick's Sporting Goods (DKS) trades at $201.95, down 5.67% in the past 24 hours, with technical indicators showing a bearish trend and key support at $198. Fundamentally, the company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.90 beating expectations, and maintains solid profitability with a 32.21% gross margin and 20.9% ROE. Recent news highlights analyst upgrades and positive coverage, while the company announced a $1.25 dividend payable in June 2026.
The outlook for DKS is mixed; analyst consensus is bullish with a $263.22 price target and no sell ratings, but technical weakness and a recent decline pose near-term risks. Investment opportunities include undervaluation based on a P/E of 19.96 and accelerating sales growth, while risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder litigation news.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
